复发性肺癌再程放疗:剂量与2年生存率的关联
本文通过系统检索20项研究(675例NSCLC患者)分析再程放疗剂量与2年总生存率(OS2-yr)的关联。多变量模型显示OS2-yr仅与再程放疗剂量显著相关,预测30%和50% OS2-yr所需的再程放疗EQD2分别为49.8 Gy10和76.5 Gy10。结论支持再程放疗靶剂量EQD2>50 Gy10,生存率随剂量增加持续至85 Gy10。
要点
- 再程放疗剂量是复发性NSCLC患者2年总生存率的独立预测因素。
- 达到30%和50% OS2-yr所需再程放疗EQD2分别为49.8 Gy10和76.5 Gy10。
- 合理靶剂量为EQD2>50 Gy10,生存获益持续至85 Gy10。
核心结论
- 复发性NSCLC再程放疗后2年总生存率与再程放疗剂量显著相关。
- 再程放疗合理靶剂量为EQD2>50 Gy10,生存率随剂量增加持续至85 Gy10。
研究设计与样本
- 本文为基于文献的系统分析,检索以NSCLC患者为主、报告2年总生存率和放疗剂量的研究。
- 共纳入20项合适研究,合计675例患者。
- 采用逻辑回归分析OS2-yr与治疗及患者因素的关联,并计算达到30%和50% OS2-yr所需剂量。
主要发现
- 单变量模型中,OS2-yr与初始放疗剂量、再程放疗剂量和化疗使用显著相关,与治疗间隔无关。
- 根据AIC选择的最佳多变量模型仅包含再程放疗剂量(p<0.05),模型拟合良好(Hosmer-Lemeshow p=0.385)。
- 该模型预测30%和50% OS2-yr对应的再程放疗EQD2分别为49.8 Gy10(95%CI 36.4, 58.0 Gy10)和76.5 Gy10(95%CI 70.8, 82.7 Gy10)。
关键数值与推荐
- 再程放疗EQD2达到49.8 Gy10时预测OS2-yr为30%(95%CI 36.4, 58.0 Gy10)。
- 再程放疗EQD2达到76.5 Gy10时预测OS2-yr为50%(95%CI 70.8, 82.7 Gy10)。
- 推荐再程放疗靶剂量EQD2>50 Gy10,生存率随剂量增加持续至85 Gy10。
临床怎么用
- 对复发NSCLC患者考虑根治性再程放疗时,可将EQD2>50 Gy10作为合理靶剂量。
- 在安全约束允许下,应争取更高再程放疗剂量以追求更高2年生存率,生存获益可持续至85 Gy10。
局限性
- 分析基于文献汇总数据而非个体患者数据,可能存在发表偏倚和混杂。
- 部分研究信息如治疗间隔、PTV大小和同步化疗使用情况并非全部可得。
- 纳入研究数量有限(20项,675例),结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Loco-regional recurrence is seen in up to 50 % of patients with non-small cell lung cancer (NSCLC) by 2 years after curative intent radiotherapy (RT). For these patients, radical re-irradiation (re-RT) is possible, but data is lacking regarding efficacy and radiation dose response, especially about conventionally fractionated re-irradiation. We analysed associations between survival following re-irradiation and RT dose, to guide clinicians regarding target re-RT dose, and predict re-treatment efficacy. MATERIAL AND METHODS: We performed a literature search for studies primarily comprised of NSCLC patients that detailed 2-year overall survival (OS2-yr) rates and delivered doses. These data were collated with intervals between treatments, PTV sizes and use of concurrent chemotherapy where this information was available. Logistic regression analyses of associations between OS2-yr and treatment and patient factors were carried out. Doses required for 30% and 50% OS2-yr were calculated. RESULTS: We identified 20 suitable studies (675 patients). In univariable models, OS2-yr was significantly associated with the initial RT dose, re-RT dose and chemotherapy use but not the interval. The best multivariable OS2-yr model according to the Akaike Information Criterion included only the re-RT dose (p < 0.05) and described the data well (Hosmer-Lemeshow p-value = 0.385). This model predicted OS2-yr rates of 30 % and 50 % at re-RT equivalent doses in 2 Gy fractions (EQD2s) of 49.8 Gy10 (95 % CI 36.4, 58.0 Gy10) and 76.5 Gy10 (95 % CI 70.8, 82.7 Gy10) respectively. CONCLUSION: OS2-yr following re-RT of recurrent NSCLC is significantly associated with retreatment dose. A reasonable target dose for re-RT is EQD2s > 50 Gy10 with survival rates continuing to increase to 85 Gy10.
引用
- Rulach R, Harrow S, Chalmers AJ, et al. Re-irradiation of recurrent lung tumours: Associations between dose and 2-year survival. Clin Transl Radiat Oncol. 2025. PMID: 40895776. doi:10.1016/j.ctro.2025.101036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。